Capricor Therapeutics, Inc. (CAPR) Cash Flow Statement

The persistent gap where operating cash outflows are larger than net losses suggests that non-cash charges like depreciation and stock-based compensation are not fully offsetting the cash consumed by working capital and other operational needs. This pattern, seen across all quarters, implies the company's cash burn is structurally embedded in its operations, not merely an accounting artifact.

The FCF trajectory reveals a company in a deepening cash burn phase, with the deficit expanding by nearly 20x over ten quarters. This acceleration is driven by both growing operating losses and episodic capital expenditures, confirming that the business model is currently a significant cash drain without a clear path to self-funding.

The erratic nature of CapEx, with massive one-quarter outlays followed by minimal spending, suggests these are likely related to specific asset acquisitions or facility investments rather than ongoing operational needs. This volatility makes forecasting future capital requirements difficult and indicates that major investment decisions are being made in discrete, large-scale events.

The modest and inconsistent impact of working capital on cash flow is consistent with a pre-commercial or early-stage biotech with minimal inventory and receivables. The lack of a predictable pattern indicates that cash management is not a primary lever for conserving capital at this stage, with the core burn driven by R&D and operating expenses.

The complete absence of shareholder returns is expected for a cash-burning, pre-revenue biotech. The minimal acquisition activity suggests a focus on internal pipeline development rather than inorganic growth. All available cash is being consumed to fund the operating deficit and periodic capital investments.